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MAP kinase-tocopheryl phosphate, a phosphoric acid ester ofα-tocopherol, in health beneﬁts
was tested gavaging this compound (5 mg/kg body wt) to a group of rats for a period of thirty days while the
control ratswere givenwater only. After thirty days, the ratswere sacriﬁced, the hearts excised, and the isolated
hearts were perfused byworkingmode. Both control and experimental hearts were subjected to 30-min global
ischemia followed by 2 h of reperfusion. The tocopheryl phosphate fed rats exhibited signiﬁcant cardio-
protection as evidenced by improved ventricular performance and reduced myocardial infarct size and
cardiomyocyte apoptosis. Supplementation with α-tocopheryl phosphate converted MAP kinase-induced
death signal into a survival signal by enhancing anti-apoptotic p42/44 ERK kinase and p38 MAPKβ and
reducing pro-apoptotic proteins p38 MAPKα and JNK. In concert, the phosphorylation of pro-apoptotic c-Src
was also reduced. Tocopheryl phosphate increased the DNA binding of the redox-sensitive transcription factor
NFκB and potentiated the activation of anti-death protein Bcl-2 and survival signaling protein Akt. The results
of this study demonstrated for the ﬁrst time that tocopheryl phosphate could ameliorate myocardial ischemic
reperfusion injury by converting ischemia/reperfusion-mediated death signal into a survival signal by
modulating MAP kinase signaling.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Epidemiologic evidence exists in the literature to support the notion
that vitamin E, especiallyα-tocopherol can reduce risk of coronary heart
disease [1,2]. Experimental studies using laboratory animals have sup-
ported cardioprotective abilities ofα-tocopherol [3–5]; but randomized
clinical trials have demonstratedvery little, if any, beneﬁt fromvitamin E
supplementation. For example, many large prospective studies includ-
ing MONICA [Monitoring Trends in Cardiovascular Disease] trial
organized by WHO [World Health Organization], NHS [Nurses' Health
Study], and HPPS [health Professionals' Follow-up Study] showed only
a little evidence in favor of cardioprotective effectiveness of vitamin E
[6–8].
Recently, an ester derivative of phosphate with the hydroxyl group
of tocopherol, α-tocopheryl phosphate ester, has been described as assure; LVdp/dt, Maximum ﬁrst
enyl tetrazoliumchloride;KHB,
rfusion; WHO, World Health
itogen-activated protein kinase
ter, University of Connecticut,
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ll rights reserved.novel natural form of tocopherol [9,10]. Similar to α-tocopherol,
α-tocopheryl phosphate is ubiquitously present in biological tissues as
well as plant kingdom [11]. One of the major differences between
α-tocopherol andα-tocopheryl phosphate is that the former is readily
oxidized by oxygen while the later is quite stable against oxidation.
α-Tocopherol is practically insoluble in water whereas α-tocopheryl
phosphate is water soluble [12]. Very little information is available
about biological and/or physiological effectiveness of α-tocopheryl
phosphate. A recent study has shownatherosclerotic-preventing effect
of α-tocopheryl phosphate, and such effect was more pronounced
than that of the acetate derivative [13]. It has been also shown that
α-tocopheryl phosphate is highly resistant to hydrolysis, both chem-
ical and enzymatic indicating that its effect is not related to the
hydrolytic liberation of free tocopherol [12,13,18]. In a few studies it
was shown that α-tocopheryl phosphate showed more potency than
the non esteriﬁed molecule possibly behaving as an activated form of
tocopherol [12,18].
We reasoned that because of these properties, α-tocopheryl phos-
phate could serve as a superior cardioprotective compound. To test this,
a group of ratswere fedα-tocopheryl phosphate [5mg/kg bodywt] for a
month. After 30 days, the rats were sacriﬁced, the hearts were excised
and isolated hearts were subjected to 30-min ischemia followed by
2 h reperfusion. The results showed signiﬁcant cardioprotectionwith
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tion and reduced myocardial infarction and cardiomyocyte apoptosis
when compared with a control group. α-Tocopheryl phosphate also
generated a survival signal against ischemia reperfusion injury by
inducing the activation of Akt and Bcl-2.
2. Materials and methods
2.1. Chemicals
α-Tocopheryl phosphate was obtained from Phosphagenics Ltd, Australia. All other
chemicals were of analytical grade and were obtained from Sigma Chemical Company
(St. Louis, MO), unless otherwise speciﬁed.
2.2. Animals
All animals used in this study received humane care in compliance with the Animal
Welfare Act and other federal statutes and regulations relating to animals and experiments
involving animals and adheres to principles stated in the Guide for the Care and Use of
Laboratory Animals, NRC Publication, 1996 edition. Sprague Dawley male rats weighing
between 250–300 g were used for the experiment. The rats were randomly assigned to
two groups: control and treated. The rats were fed ad libitum regular rat chow with free
access to water. The treated rats were gavaged with α-tocopheryl phosphate (5 mg/kg
body wt/day) for thirty days while the control group received water only.
The rats were anesthetized with sodium pentobarbital (80 mg/kg, bw i.p.), (Abbott
Laboratories, North Chicago, IL, USA) and anticoagulant with heparin sodium (500 IU/kg,
bw i.v.) (Elkins-Sinn Inc., CherryHill, NJ, USA) injection. After ensuring sufﬁcient depth of
anesthesia thoracotomy was performed, hearts were perfused in the retrograde
Langendorff mode at 37 °C at a constant perfusion pressure of 100 cm of water
(10 kPa) for a 5-min washout period [14]. The perfusion buffer used in this study
consisted of a modiﬁed Krebs–Henseleit bicarbonate buffer (KHB) (in mM sodium
chloride 118, potassium chloride 4.7, calcium chloride 1.7, sodium bicarbonate 25,
potassium biphosphate 0.36, magnesium sulfate 1.2, and glucose 10). The Langendorff
preparation was switched to the working mode following the washout period.
At the end of 10 min, after the attainment of steady state cardiac function, baseline
functional parameters were recorded. The hearts were then subjected to 30 min of
global ischemia followed by 2 h of reperfusion. The ﬁrst 10min of reperfusionwas in the
retrograde mode to allow for post-ischemic stabilization and there after, in the
antegrade working mode to allow for assessment of functional parameters, which were
recorded at 30-, 60- and 120-min reperfusion.
2.3. Assessment of cardiac function
Aortic pressure was measured using a Gould P23XL pressure transducer (Gould
Instrument Systems Inc., Valley View, OH, USA) connected to a side arm of the aortic
cannula, the signal was ampliﬁed using a Gould 6600 series signal conditioner and
monitored on a CORDAT II real-time data acquisition and analysis system (Triton
Technologies, San Diego, CA, USA) [14]. Heart rate (HR), left ventricular developed pressure
(LVDP) (deﬁned as the difference of the maximum systolic and diastolic aortic pressures),
and the ﬁrst derivative of developed pressure (dp/dt) were all derived or calculated from
the continuously obtained pressure signal. Aortic ﬂow (AF) was measured using a
calibratedﬂow-meter (Gilmont Instrument Inc., Barrington, IL, USA)andcoronaryﬂow(CF)
was measured by timed collection of the coronary efﬂuent dripping from the heart.
2.4. Infarct size estimation
At the end of reperfusion, a 1% (w/v) solution of triphenyl tetrazolium chloride in
phosphate buffer was infused into aortic cannula for 20 min at 37 °C [15]. The hearts
were excised and stored at −70 °C. Sections (0.8 mm) of frozen heart were ﬁxed in 2%
paraformaldehyde, placed between two cover slips and digitally imaged using a
Microtek Scan Maker 600z. To quantify the areas of interest in pixels, a NIH image 5.1
(a public-domain software package) were used. The infarct size was quantiﬁed and
expressed in pixels.
2.5. TUNEL assay for the assessment of apoptotic cell death
Immunohistochemical detection of apoptotic cells was carried out using TUNEL
[15] using Dead-End TM Fluorometric TUNEL System (Promega, Madison, WI). The
heart tissues were immediately put in 10% formalin and ﬁxed in an automatic tissue-
ﬁxing machine. The tissues were carefully embedded in the molten parafﬁn in metallic
blocks, covered with ﬂexible plastic moulds and kept under freezing plates to allow the
parafﬁn to solidify. The metallic containers were removed and tissues became
embedded in parafﬁn on the plastic moulds. Prior to analyzing tissues for apoptosis,
tissue sections were deparafﬁnized with xylene and washed in succession with
different concentrations of ethanol (absolute, 95%, 80%, 70%). Then the TUNEL
experiment was done according to the manufacturer's instructions. The ﬂuorescence
staining was viewed with a ﬂuorescence microscope (AXIOPLAN2 IMAGING) (Carl Zeiss
Microimaging. Inc. NY). The number of apoptotic cells was counted and expressed as a
percent of total myocyte population.2.6. Preparation of cytosolic, nuclear and mitochondrial extracts
Tissues (frozen in liquid nitrogen and stored at −80 °C) were homogenized in 1 ml
buffer A (25 mM Tris–HCl, pH 8, 25 mM NaCl, 1 mM Na–Orthovanadate, 10 mM NaF,
10 mM Na–Pyrophosphate, 10 nM Okadaic acid, 0.5 mM EDTA, 1 mM PMSF, and 1×
Protease inhibitor cocktail) in a Polytron-homogenizer. Homogenates were centrifuged
at 2000 rpm at 4 °C for 10 min and the nuclear pellet was resuspended in 500 μl of
Buffer A with 0.1% Triton X-100 and 500 mM NaCl. Supernatant from the above
centrifugation was further centrifuged at 10,000 rpm at 4 °C for 20 min, and the
resultant supernatant was used as cytosolic extract. The mitochondrial pellet was
resuspended in 200–300 μl of Buffer A with 0.1% Triton X-100. The nuclei pellet and
mitochondrial pellet were lysed by incubation for 1 h on ice with intermittent tapping.
Homogenates were then centrifuged at 14,000 rpm at 4 °C for 10 min, and the
supernatant was used as nuclear lysate andmitochondrial lysate respectively. Cytosolic,
nuclear and mitochondrial extracts were aliquoted, snap frozen and stored at −80 °C till
use. Total protein concentration in cytosolic, nuclear and mitochondrial extract was
determined using BCA Protein Assay Kit (Pierce, Rockford, IL).
2.7. Western blot analysis
Proteins were separated in SDS-PAGE and transferred to nitrocellulose ﬁlters [16].
Filters were blocked in 5% nonfat dry milk, and probed with primary antibody for
overnight at 4 °C. Primary antibodies such as Bcl-2, Akt, phospho-Akt(Ser 473), P38 β
and Glyceraldehyde-6-phosphate dehydrogenase (GAPDH) were obtained from Santa
Cruz Biotechnology, Santa Cruz, CA; whereas Src, phospho-Src (Ser 416), JNK, phospho-
JNK (Thr183/Tyr185), P38 alpha, ERK, phospho-ERK (Thr180/Tyr182) were obtained
from Cell Signaling Technology, Beverly, MA. All primary antibodies were used at the
dilution of 1:1000. Protein bands were identiﬁed with horseradish peroxidase
conjugated secondary antibody (1:2000 dilution) and Western Blotting Luminol
Reagent (Santa Cruz Biotechnology, Santa Cruz, CA). GAPDH was used as loading
control. The resulting blots were digitized, subjected to densitometric scanning using a
standard NIH image program, and normalized against loading control.
2.8. EMSA for DNA binding activity of NFκB
To determine NFκB binding activity, nuclear proteins were isolated from the heart
according to the method described previously [17]. In short, about 150mg of left ventricle
from heart tissue was homogenized with ice-cold buffer A (20 mM HEPES, pH7.9, 20%
glycerol, 10 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT. 0.1% Triton X-100 and
protease inhibitors {PMSF.leupeptin, aprotinin and pepstatin}) in homogenizer. Homo-
genates were centrifuged at 2000 rpm at 4 °C for 15 min and the nuclear pellet was
resuspended in ﬁve volumes of buffer B that was essentially buffer A except containing
500 mM NaCl. The nuclei were lysed by incubation for one hour on ice with intermittent
tapping. Homogenates were then centrifuged at 10,000 rpm at 4 °C for 15 min
supernatants were aliquoted and snap frozen at −80 °C until use. Protein concentration
was estimated using the Pierce Protein Assay kit (Pierce Chemical Co., Rockford, IL).
NFκB oligonucleotide (5′-AGTTGAGGGGACTTTCCCAGG-3′) (2 μl [5 ng/μl]) was
labeled using 5 μl 10× T4 polynucleotide kinase as previously described [17]. DNA–
protein binding reaction was carried out in 40 μl binding buffer (20 mM HEPES, pH7.9,
3% glycerol, 60 mM NaCl, 1.5 mMMgCl2, 1.0 mM EDTA and 1 mM DTT) containing 30 μg
nuclear extract, 1 μg poly (dI–dC), and 32P-labeled probe (40,000 CPM) on ice for
40 min. Protein–DNA complex were fractionated on 8% acrylamide gel in 0.5× TBE at
200 V, 4 °C until the dye hit the bottom. After electrophoresis, gels were dried and
exposed to Kodak X-ray ﬁlm at −80 °C. Autoradiographic results were evaluated
quantitatively by an image analyzer. The binding signal from each sample was
measured in the same sized area. Competition reaction was carried out using 100-fold
molar excess unlabeled competitor DNA. Therefore, the speciﬁc binding was calculated
by subtracting non speciﬁc binding from total binding.
2.9. Statistical analysis
The values formyocardial functional parameters, total and infarct volumesand infarct
sizes and cardiomyocyte apoptosis are all expressed as themean±standard error ofmean
(SEM). Analysis of variance test followedbyBonferroni's correctionwasﬁrst carried out to
test for any differences between the mean values of all groups. If differences between
established, the values of the treated groups were compared with those of the control
group by a modiﬁed t-test. The results were considered signiﬁcant if pb0.05.
3. Results
3.1. Effects of α-tocopheryl phosphate on left ventricular function
Fig. 1 shows the cardiac function obtained in rats pretreated with
5mg/kg bodywt ofα-tocopheryl phosphate or vehicle only. The hearts
were subjected to 30 min of ischemia followed by 120 min of reper-
fusion. There was no signiﬁcant difference in the baseline parameters
between the groups. In hearts treated with 5 mg/kg body wt of
α-tocopheryl phosphate a signiﬁcant post-ischemic recovery in aortic
Fig. 1. The effect of α-tocopheryl phosphate on heart rate, coronary ﬂow, aortic ﬂow, left ventricular developed pressure, and ﬁrst derivative of left ventricular developed pressure
(dp/dt). n=6 in each group. Mean±SEM, comparisons were made to the values of drug-free control group. ⁎pb0.05. RE: reperfusion.
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ative of maximum left ventricle developed pressure (LVDPmax dp/dt)
was observed after 30-, 60-, and 120min of reperfusion in comparison
with the vehicle treated control group. Similarly to the AF, LVDP, and
LVDP max dp/dt signiﬁcant change was found in coronary ﬂow (CF),
but only after 2 h of reperfusion. The heart rate did not show signiﬁ-
cant difference between the two groups.
3.2. Effects of α-tocopheryl phosphate on myocardial infarct
After 30-min ischemia followed by 120 min of reperfusion
myocardial infarct size was determined by TTC method. Fig. 2 shows
α-tocopheryl phosphate treatment signiﬁcantly reduced the infarct
size compared to the vehicle treatment. In case of vehicle treatment
the infarct size was 36.5±2.5%, in the α-tocopheryl phosphate treated
group the infarct size was only 21.8±2.1%.
3.3. Effects of α-tocopheryl phosphate on cardiomyocyte apoptosis
As shown in Fig. 3, in case of ischemic control group rat (I/R)
cardiomyocyte apoptosis determined by TUNEL method was about
30±2% at the end of reperfusion. There was very less amount of
apoptotic cells 5±0.5% in the hearts perfused with the KHB buffer
without subjecting to ischemia and reperfusion (control). Again,α-tocopheryl phosphate signiﬁcantly reduced the number of apopto-
tic cardiomyocytes to 11±1.5%.
3.4. Effects of α-tocopheryl phosphate on map kinase signaling
We examined the effect of α-tocopheryl phosphate on MAP kinase
signaling. Fig. 4 shows that ischemia can reduce the activity of anti-
apoptotic ERK 44/42 and p38 MAPKβ but treatment with α-tocopheryl
phosphate can prevent this reduction of these anti-apoptotic members.
Fig. 4 also shows that ischemia reperfusion can increase the activity of
pro-apoptotic p38MAPKα and JNK but these activations were reduced
after treatment with α-tocopheryl phosphate.
3.5. Effects of α-tocopheryl phosphate on the DNA binding of NFκB
To check whether α-tocopheryl phosphate induces NFκB activities,
we performed electrophoretic mobility shift assay with a double
stranded radiolabeled oligonucleotide harboring the canonical NFκB
binding sequence (5′-AGTTGAGGGGACTTTCCCAGG-3′). As shown in
Fig. 5, NFκB binding activity diminished upon ischemia as compared
to non ischemic control while it substantially increased for the
α-tocopheryl phosphate treated hearts. Out of four NFκB binding
activities such induced, at least three (C1–3) had p65 as a constituent
as evidenced from super-shift assay.
Fig. 4. Western blot analysis to check the effects of α-tocopheryl phosphate on the
phosphorylation of p44/42 MAP kinase, JNK and the expression of p38β and p38α. The
isolated rat hearts were perfused for 15minwith KHB buffer. The hearts were subjected to
30-min global ischemia followed by 2 h of reperfusion in theworkingmode. At the end of
the experiments, the hearts were frozen at liquid nitrogen. The phosphorylated proteins
Fig. 2. The effect of α-tocopheryl phosphate on myocardial infarct size was determined
by TTC method. n=3 in each group. Mean±SEM, comparisons were made to the values
of drug-free control group. ⁎pb0.05.
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We examined the effects of α-tocopheryl phosphate on the
members of the survival signal pathway. Fig. 6 shows the results.
The phosphorylation of Akt was reduced after ischemia/reperfusion,
but signiﬁcantly upregulatedwithα-tocopheryl phosphate treatment.Fig. 3. Effects of α-tocopheryl phosphate on cardiomyocyte apoptosis. Isolated heart
from control (non ischemic) rats were perfused with the KHB buffer without subjecting
to ischemia and reperfusion. Isolated hearts from ischemic control rats [I/R] (n=6) and
α-tocopheryl phosphate treated rats (n=6) were subjected to 30 min of global ischemia
followed by 2 h reperfusion. Cardiomyocyte apoptosis was measured by Tdt-mediated
dUTP nick end labeling with Promega kit. Panel A represents total number of cells (red
channel). Panel B represents total number of apoptotic cells (green channels). Panel C
represents merged image of panel A and panel B (yellow dots in merged channel are the
apoptotic cells). Values are Mean±SEM ⁎pb0.05 vs. control. †pb0.05 vs. I/R.
Representative photomicrographs are shown below the bar graphs.
are shown on the top of non phosphorylated proteins, which also served as the controls.
GAPDHwasusedas a loading control for p38β andp38α. Figures are representative images
of three different groups, and each experiment was repeated at least thrice. Values are
Mean±SEM. ⁎pb0.05 vs. control, †pb0.05 vs. I/R.
Fig. 5. Induction of NFκB binding activity by α-tocopheryl phosphate in rat heart. Nuclear
extracts were prepared from hearts isolated from rats fed with α-tocopheryl phosphate or
the vehicle followed by ischemia reperfusion. Thirty micrograms of extracts were tested for
NFκB binding activities by electrophoretic mobility shift assay using radiolabeled cognate
binding site (5′-AGTTGAGGGGACTTTCCCAGG-3′) as probes. Lane A: control; lane B:
ischemia/reperfusion; lane C: α-tocopheryl phosphate treatment followed by ischemia
reperfusion; laneD: extract in laneCplusp65antibody (1:5dilution); LaneE: extract in laneC
plus p65 antibody (undiluted); lane F: extract in lane C plus 100-foldmolar excess unlabeled
NFκB binding sequence as competitor. The NFκB speciﬁc complexes are marked as C1–4, of
which C1–3 is super-shifted by the p65 antibody and thus contains p65 as a constituent.
Fig. 6. Western blot analysis of p-Akt, Akt, p-Src, Src, and Bcl-2 proteins in the heart
tissue obtained from control (non ischemic), I/R (ischemic control) and α-tocopheryl
phosphate treated group. The isolated rat hearts were perfused for 15 min with KHB
buffer. The hearts were then subjected to 30-min global ischemia followed by 2 h of
reperfusion in the working mode. At the end of the experiments, the hearts were frozen
at liquid nitrogen temperature. The phosphorylated proteins are shown on the top of
non phosphorylated proteins, which also served as the controls. GAPDH was used as a
loading control for Bcl-2 protein. Figures are representative images of three different
groups, and each experiment was repeated at least thrice. Values are Mean±SEM.
⁎pb0.05 vs. control. †pb0.05 vs. I/R.
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but in case of α-tocopheryl phosphate treated group the activation of
pro-apoptotic factor c-Src was signiﬁcantly reduced. Bcl-2 was
downregulated after ischemia/reperfusion, but tocopheryl phosphate
prevented the loss of Bcl-2 protein due to ischemia/reperfusion.
4. Discussion
The present study demonstrates that nutritionally supplemented
α-tocopheryl phosphate can reduce myocardial ischemia reperfusion
injury as evidenced by its ability to improve ventricular function and
reduce infarct size and cardiomyocyte apoptosis. Supplementation
with tocopheryl phosphate appears to potentiate a survival signal
through the activation of Akt and Bcl-2 and by switching MAP kinase-
induced death signal into a survival signal.
α-Tocopheryl phosphate is a water soluble phosphoric acid ester of
α-tocopherol that exists ubiquitously in both animal andplant kingdom.
Nutritionally supplemented tocopheryl phosphate results in a minor
increase of the non esteriﬁed form [18] therefore the effects of
α-tocopheryl phosphate appeared not to be related to the release of free
tocopherol. Asmentioned earlier,α-tocopheryl phosphate is resistant to
hydrolysis and oxidation, and it can liberateα-tocopherol only by strong
alkaline hydrolysis or very slowly by alkaline phosphatase [12].
Only recently, health beneﬁts of α-tocopheryl phosphate have
become apparent. For example, α-tocopherol phosphate has recently
been found to protect against ultraviolet B-induced damage in
cultured mouse skin [19]. A mixture of α-tocopheryl phosphate and
di-α-tocopheryl phosphate inhibited cell proliferation and CD36
mRNA and protein expression leading to the inhibition of oxLDL
uptake [13]. Another recent study showed that the atherosclerotic-
preventing effect and CD36 inhibitory effect of the phosphate
derivative were more pronounced than the acetate derivative of α-
tocopherol [20]. Data on the tissue distribution of α-tocopheryl
phosphate after supplementation are not available yet. Consequently,
a distinction between a pharmacological and a nutritional interven-
tion is not possible at the present time However, the present studydemonstrates the ability of α-tocopheryl phosphate to reduce
myocardial ischemia reperfusion injury by enhancing ventricular
performance and reducing myocardial infarct size and cardiomyocyte
apoptosis.
Existing evidence supports the role ofα-tocopheryl phosphate as a
signaling molecule. However, direct evidence of performing intracel-
lular signaling was never shown previously. To the best of our
knowledge, the present study reports for the ﬁrst time that tocopheryl
phosphate can ameliorate myocardial ischemia reperfusion injury by
activating survival signal through the phosphorylation of Akt and
enhancing the expression of anti-death protein Bcl-2. Our study
clearly demonstrated a reduction of Akt phosphorylation in the
ischemic reperfused myocardium. Not only did α-tocopheryl phos-
phate prevent such a reduction of Akt phosphorylation, it actually
increased the phosphorylation over the baseline. Similarly, Bcl-2 was
almost negligible in the ischemic reperfused heart, but increased
several-fold with α-tocopheryl phosphate. These ﬁndings are con-
sistent with the previous reports, where Akt acts at the level of
mitochondria to release cytochrome c via Bcl-2 in adult cardiomyo-
cytes [21]. PI-3-kinase-Akt signaling pathway appears to play a critical
role in the prevention of ischemia/reperfusion-induced cell death
[22].
The pro-apoptotic factor c-Src was also signiﬁcantly lowered as a
result of α-tocopheryl phosphate treatment. The Src kinase belongs to
the family of non receptor tyrosine kinases, which modulate a wide
variety of intracellular signaling. Including those mediating DNA
synthesis and proliferation. Activation of Src kinase is associated with
many degenerative diseases including ischemic heart disease [23].
Myocardial ischemia reperfusion causes an induction of c-Src protein
expression, and inhibition of c-Src with PPI can restore the extent of
cellular injury [24]. The present results also support these previous
reports.
Interestingly, α-tocopheryl phosphate could modulate the MAP
kinase signaling by convertingMAP kinase-induced death signal into a
survival signal. Ischemia reperfusion generated a death signal as a
result of reduced activity of anti-apoptotic ERK 42/44 and p38MAPKβ
in concert with an activation of pro-apoptotic p38MAPKα and JNK.
α-Tocopheryl phosphate completely reversed the MAP kinase sig-
naling by inducing the activation of ERK 42/44 and p38MAPKβ and
the reduction of JNK and p38MAPKα. A signiﬁcant number of reports
exist in the literature demonstrating a crucial role of MAP kinase sig-
naling in modulating the death signal induced by ischemia/reperfu-
sion [25]. Many cardioprotective agents function by changing such
death signal into survival signal. For example, ischemic precondition-
ing protects the ischemic myocardium by activating p42/44 ERK
and p38MAPKβ and reducing p38MAPKα and JNK phosphorylation
[26]. P38 MAPK signaling appears to be of particular interest, as one
of the isomers p38MAPKα potentiates a death signal while another
isomer p38MAPKβ potentiates a survival signal [27]. It is interesting to
note that tocopheryl phosphate can differentially regulate p38MAPK
signaling.
A number of recent studies have determined an essential role of
NFκB in myocardial survival following ischemia and reperfusion. For
example, myocardial protection through ischemic preconditioning
cannot be achieved unless there is an increased DNA binding of NFκB
[28]. The results of the present study support the previous ﬁndings of
reduced NFκB in the ischemic reperfused myocardium, and further
demonstrate a signiﬁcant increase the DNA binding activity of NFκB
after α-tocopheryl phosphate treatment.
In summary, the results of the present study demonstrate the
cardioprotective ability of α-tocopheryl phosphate. Cardioprotection
was achieved by changing ischemia reperfusion-mediated death
signal into a survival signal by modulating MAP kinase signaling and
inhibition of c-Src activity. The anti-death signal was realized through
Akt-Bcl-2 survival pathway indicating the ability of α-tocopheryl
phosphate to generate a survival signal.
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